Aptevo Therapeutics (APVO) to Release Earnings on Tuesday

Aptevo Therapeutics (NASDAQ:APVO) is expected to be issuing its results after the market closes on Tuesday, May 12th. Analysts expect the company to announce earnings of ($5.60) per share for the quarter.

Aptevo Therapeutics (NASDAQ:APVO) last released its earnings results on Thursday, March 26th. The biotechnology company reported $118.23 EPS for the quarter, beating the consensus estimate of ($8.10) by $126.33. On average, analysts expect Aptevo Therapeutics to post $-21 EPS for the current fiscal year and $-19 EPS for the next fiscal year.

Aptevo Therapeutics Stock Performance

Shares of NASDAQ:APVO opened at $4.97 on Monday. The stock’s 50-day moving average price is $5.07 and its two-hundred day moving average price is $12.38. Aptevo Therapeutics has a 12-month low of $3.80 and a 12-month high of $258.01. The firm has a market cap of $5.86 million, a price-to-earnings ratio of 0.00 and a beta of 1.64.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Aptevo Therapeutics stock. Virtu Financial LLC purchased a new stake in shares of Aptevo Therapeutics Inc. (NASDAQ:APVO) during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund purchased 38,282 shares of the biotechnology company’s stock, valued at approximately $56,000. Virtu Financial LLC owned approximately 1.16% of Aptevo Therapeutics as of its most recent SEC filing. Institutional investors and hedge funds own 8.06% of the company’s stock.

Analyst Ratings Changes

Several brokerages have recently weighed in on APVO. Weiss Ratings upgraded shares of Aptevo Therapeutics from a “sell (e)” rating to a “sell (e+)” rating in a report on Friday. Wall Street Zen raised shares of Aptevo Therapeutics from a “sell” rating to a “hold” rating in a research report on Sunday, March 29th. One investment analyst has rated the stock with a Strong Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Hold”.

About Aptevo Therapeutics

Aptevo Therapeutics, Inc is a clinical-stage biopharmaceutical company headquartered in Seattle, Washington, focused on the discovery and development of novel immunotherapies for oncology and autoimmune diseases. Founded in 2012 as a spin-off from Emergent BioSolutions, the company builds on expertise in protein engineering and translational research to create targeted biologics that engage the body’s immune system.

The company’s core technologies include the ADAPTIR platform, which enables the design of bispecific and multispecific protein scaffolds with customizable binding domains, and the KNOCKOUT platform, which incorporates non-natural amino acids to enhance therapeutic properties such as stability and half-life.